Clinical Trial

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke

Study acronym: IRIS-3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.
Protocol Amendment History 3 changes
notable Trial sites expanded: 6 -> 13 locations 2026-05-06
critical Recruitment opened 2026-04-18
notable Trial sites expanded: 1 -> 6 locations 2026-04-18
Trial Details
NCT Number NCT07509645
Lead Sponsor Capital Medical University
Conditions Ischemic Stroke
Enrollment 348 participants
Start Date 2026-04-22
Primary Completion 2027-04-20 (estimated)
Study Completion 2027-04-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-05